Objective: Understanding how individuals weigh the quality of life associated with complications and treatments is important to assessing the economic value of diabetes care and may provide insight into treatment adherence. We quantify patients' utilities (a measure of preference) for the full array of diabetes-related complications and treatments. Research Design and Methods: We conducted interviews with a multi-ethnic sample of 701 adult patients living with diabetes, attending Chicago area clinics. We elicited utilities (ratings on a 0-1 scale (0-death; 1-perfect health) for hypothetical health states by using time tradeoff questions. We evaluated 9 complication states (e.g., Diabetic Retinopathy and Blindness) and 10 treatment states (e.g., Intensive (IGC) vs. Conventional Glucose Control (CGC), and Comprehensive Diabetes Care (i.e., intensive control of multiple risk factors)). Conclusions: End-stage complications have the greatest perceived burden on quality of life; however, comprehensive diabetes treatments also have significant negative quality of life effects. Acknowledging these effects of diabetes care will be important for future economic evaluations of novel drug combination therapies and innovations in drug delivery.
Diabetes mellitus significantly increases an individual's risk of developing multiple microvascular and cardiovascular complications and the risk of these complications can be significantly reduced with intensive and comprehensive diabetes care (1) . Current recommendations for the ideal risk factor targets (e.g., glycosylated hemoglobin (HbA 1C ) <7%) and specific therapies (e.g., prophylactic aspirin) for diabetes care reflect the findings of multiple clinical trials (2) (3) (4) .
While intensive and comprehensive diabetes care may generate significant health benefits, the current level of adoption of comprehensive diabetes care is incomplete. Quality of care studies indicate that there has been a steady rise in the proportion of patients taking beneficial medications such as aspirin and that there have been reductions in the proportion of patients with poor risk factor control (5) . At the same time, large proportions of patients continue to have poor glycemic (20%), blood pressure (33%), and cholesterol control (40%) (5) . These ongoing deficiencies have led to a large public investment in diabetes quality improvement programs (6) .
The success of these quality improvement efforts depends, in part, on whether or not patients are willing to take the multiple medications that comprise comprehensive diabetes care. Patients' willingness to adopt this care is likely to be determined, in part, by their perceptions of the relative quality of life effects of complications and treatments (7; 8) . These perceptions are also critical for economic evaluations of quality improvement efforts and treatment innovations.
The development of combination drugs such as the Polypill, a proposed treatment combining an aspirin, diuretic, ACE inhibitor, beta blocker, folic acid, and statin, is motivated by the desire to simplify the treatment experience (9) . Novel insulin delivery methods are intended to eliminate the discomfort associated with insulin injections (10) . Whether these innovations will prove to be economically valuable depends on accurately accounting for the adverse quality of life effects of treatments and their downstream effects. Quality of life effects are reflected in medical cost-effectiveness analyses (CEA) using quality-of-life-weights called utilities. Utilities are quantitative measures of preference, on a 0 to 1 scale where 0 represents death and 1 represents life in perfect health (11) .
Despite the importance of understanding the utilities for treatment and complication health states related to diabetes care, there have been no systematic efforts to directly elicit utilities for the full array of complications and treatments that patients may experience. As a result, important complication and treatment states have never been accounted for in prior CEA (12) .
The utilities for several intermediate microvascular complication states (e.g. diabetic neuropathy) are unknown. Accounting for the effects of these states may influence CEA results because the incidences of intermediate complications are high compared to those of end-stage complications (3) .
Even more striking is the lack of accounting for the quality of life effects of treatments. We have previously found that accounting for the quality of life effects of treatments can alter the conclusions of CEA for intensive glucose control and this may prove to be the case for comprehensive diabetes care (13) .
We set out to systematically collect, describe, and compare patients' utilities for the full range of complications and treatments related to diabetes. From May 2004 to May 2006, we conducted  face-to-face interviews with non-demented  patients, aged 18 and older, living with diabetes, attending clinics affiliated with an academic medical center (University of Chicago, Chicago, IL) and physician offices affiliated with a suburban hospital (MacNeal Hospital, Berwyn, IL). Prospective subjects were initially identified through clinic scheduling software based on ICD-9 codes for diabetes (i.e., 250.xx).
Research Design and Methods
Randomly identified patients were sent study recruitment letters. Letters were followed by a telephone call. We performed a screening telephone mini-mental status examination and excluded patients with scores ≤ 17 (14) . We successfully contacted 2990 patients and 2398 of these patients were eligible for the study. A total 910 patients (38% of eligible subjects) scheduled interviews and 701 patients (29% of eligible subjects) completed interviews.
The average of age of subjects who completed interviews did not differ from that of other eligible patients.
Interviews took approximately one hour and were conducted by trained interviewers, in English or Spanish. All Spanish interview materials were professionally translated and back translated. We elicited utilities using the time-tradeoff method (15) . For each time-tradeoff elicitation, patients were given a description of a hypothetical health state and asked to consider life in that state. The text of all health state descriptions is available in the online appendix (http://care.diabetesjournals.org).
The health state descriptions were based upon our prior study of diabetes-related health state utilities (13) and existing descriptions in the literature. Health state descriptions were reviewed with clinical faculty at the University of Chicago and pilot tested with patients. During the time tradeoff elicitation patients were asked to give their preference for 10 years in the health state of interest and a shorter period of time in perfect health. Using the ping-pong method, patients were asked a series of iterative questions where the time in perfect health was systematically altered by yearly increments and questioning was stopped when the patient was indifferent between a given time choice. The point at which the patient was indifferent between the time choices was used to calculate the utility score (e.g., if 6 years of life in perfect health = 10 years with an amputation, the utility = 0.60).
To minimize the effects of order response bias, the order of utility assessments was randomly allocated along two dimensions of the (18) , and Diabetic Nephropathy (21)).
For each treatment state, we described the daily experience of treatments, the laboratory testing associated with treatments, and the likelihood of side effects. Patients were asked not to consider long-term effects of treatments on complications but to focus on the daily quality of life effects of treatments. We based our description of Intensive and Conventional Glucose Control on the treatment protocols and patient experiences of the United Kingdom Prospective Diabetes Study (UKPDS) (3).
With Intensive Glucose Control, patients were told that they would be more likely to be put on multiple oral agents and insulin, that the frequency of major hypoglycemic episodes would be higher, and that the need for self-glucose monitoring would be greater in order to achieve a HbA 1C less than 7% in comparison to Conventional Glucose Control (HbA 1C = 7.9%). Similarly, we used the UKPDS blood pressure trial protocols as the basis for descriptions of Intensive and Conventional Blood Pressure Control (2). Patients were told that with Intensive Blood Pressure Control they would be more likely to be put on three to four blood pressure agents in comparison to Conventional Blood Pressure Control.
Descriptions for the remaining treatment states were based on data from the medical literature (e.g., Aspirin (22) and Cholesterol lowering medication (23) 
Statistical Analysis
All analyses were performed using SAS statistical software (Release 8.1, SAS Institute Inc., Cary, NC). We describe the distribution of utilities using the mean, median, mode, and standard deviation and provide graphical illustration of the distributions of utility scores. Paired t-tests were used to compare multiple health state utilities ascertained from the same individuals. Wilcoxon rank-sum tests were used for comparisons of utilities across subgroups.
Results

Study Population
The mean age of subjects was 63 years, 42% were men, 38% were Black, and 24% were Latino ( Table 1 ). The mean duration of diabetes was 9.9 years and the mean Charlson Comorbidity Index was 2.64 (24) . Twentythree percent of patients had experienced a microvascular complication and 30% reported having cardiovascular complications. In comparison to nationally reported risk factors levels, study subjects had lower mean glucose and cholesterol levels but similar blood pressure levels (5). The majority (61%) used oral diabetes medications alone, 25% used insulin as part of their therapy, and 14% used no medications for glucose control. It is important to note that these differences in mean utilities are directly influenced by the heterogeneity in patient utilities and that this heterogeneity varied by complications and treatments. For complication states, it was common to see a heavy left-sided tail for end-stage complications. For treatment states, the majority of patients actually rated life with treatments as being close to perfect health indicating that treatments were not burdensome.
At the same time, an important minority of patients (10-18%) gave ratings that indicate that they perceived life with treatments as being a significant burden on quality of life. Our observation that there is significant heterogeneity in patient treatment preferences highlights the importance of incorporating a shared decision making approach into everyday diabetes care. Acknowledging individual patient treatment preferences may be one of the keys to translating findings from clinical trial populations to general patient populations (8) .
These utility values may be used in future costeffectiveness analyses of diabetes care. This study provides directly elicited utilities from a single population of adult patients living with type 2 diabetes. It provides an additional source of utility data that may have particular advantages when comparing alternative diagnostic or treatment options (11) . Indirect methods of utility elicitation (e.g., EuroQoL) (25; 26) have a primary advantage of ease of administration; however they may be relatively insensitive to important differences for particular treatment decisions. Directly eliciting utilities for specific health states provides a more theoretically-sound (11) and sensitive approach to detecting differences in patients' preferences regarding different health states.
The primary limitation of direct elicitation methods is the challenge of collecting such data; however, this study was carried out to overcome this limitation. This study provides utilities for complications and treatments that have never been previously considered in analyses and accounting for these utilities may shift the balance of CEA results (13) . A major insight that has not been extensively studied in previous CEA of chronic diseases is that any negative quality-of-life effect of treatment can outweigh its benefits over a population. Failure to acknowledge the quality of life effects of current treatments may lead to an overestimation of the benefits of ongoing quality improvement efforts and an underestimation of the benefits of treatment innovations (10) . It is important to note that these utilities represent patient-derived utilities and that there may still be a need to collect these health state utilities from the general population in order to accurately reflect the societal perspective in base case CEA (11) . Cost-effectiveness analyses of diabetes care have tended to rely on utilities that are available in the literature and these have tended to be patient-derived (26) .
Several limitations of this study should be considered when interpreting these results. The preferences of this particular patient population may not be representative of all patients living with diabetes. All of our patients had an established relationship with a provider and they may represent a more adherent group of patients than those in the general population. However, our study sample is ethnically and economically diverse. Our results are also limited by the fact that the validity of utility measurements cannot be directly assessed because there is no gold standard for measuring preferences. However, our patient population had significant experience with the various described health states, the order of our utility results has face validity, and our complication utilities are similar to those collected by the time-tradeoff method (27) . Another limitation of the study is that we did not formally assess the reliability of the utility ratings over time. Our comparisons of patients with and without experiences with complications and medications provide some insight into how these utilities might change over time. Finally, our utility ratings are influenced by the specific descriptions of health states provided during the survey.
This study has important implications for current policies and programs that are designed to enhance the quality of chronic disease management.
Many of these programs essentially encourage patients to add more medications to their treatment regimen. In the near future, the results of the Action to Control Cardiovascular Risk in Diabetes trial may actually lead to even lower risk factor goals that will require even greater use of medications in order to achieve them. Our study results show that taking multiple medications on a routine basis represents a significant burden for many patients. Our study helps elucidate what facets of medication taking concern patients, and provides a starting point from which we can think about how to overcome these concerns with patients. Quality of life related to treatments will likely improve if we can simplify or modify current treatments through treatment innovations. Without such technological innovations, we may still be able to allay patient concerns by educating patients very early on in their disease about the true nature of optimal diabetes care, by incorporating their preferences into treatment decisions, and by acknowledging patient preferences and quality of life concerns in public health efforts to improve the quality of diabetes care. 
